Recent events
Recent events tied to this brand in public sources.
Back to profile5 entries
2021
NeuroBo appoints Gil Price as president and CEO
NeuroBo Pharmaceuticals announced that it appointed Gil Price as president and chief executive officer. Price will replace Richard J. Kang, who was to step down later that month while remaining on the board.
2021
NeuroBo completes $10 million private placement
NeuroBo reported the successful completion of a private placement of 2.5 million common shares and warrants, with aggregate gross proceeds of $10.0 million and net proceeds of approximately $9.2 million. The source dates this completion to the first quarter of 2021.
2020
NeuroBo acquires ANA Therapeutics
NeuroBo Pharmaceuticals acquired ANA Therapeutics on December 31, 2020. ANA became a wholly owned subsidiary of NeuroBo.
2020
NeuroBo appoints Douglas J. Swirsky to its board
NeuroBo Pharmaceuticals appointed Douglas J. Swirsky to its Board of Directors, effective September 1, 2020; he will also serve on the Audit Committee.
2020
NeuroBo reports first-quarter 2020 results
NeuroBo Pharmaceuticals announced financial results for the first quarter ended March 31, 2020, reporting a net loss of approximately $4.8 million and cash and cash equivalents of $9.8 million as of March 31.